NAMSW
Income statement / Annual
Last year (2023), NewAmsterdam Pharma Company N.V.'s total revenue was $12.76 M,
a decrease of 86.69% from the previous year.
In 2023, NewAmsterdam Pharma Company N.V.'s net income was -$176.94 M.
See NewAmsterdam Pharma Company N.V.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$12.76 M
|
$95.91 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$12.76 M |
$95.91 M |
$0.00 |
$0.00 |
| Gross Profit Ratio |
1 |
1 |
0 |
0 |
| Research and Development
Expenses |
$159.42 M
|
$81.01 M
|
$25.46 M
|
$4.05 M
|
| General & Administrative
Expenses |
$30.41 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$3.67 M
|
$1.60 M
|
$858,392.00
|
$11,000.00
|
| Selling, General &
Administrative Expenses |
$29.77 M
|
$18.22 M
|
$5.27 M
|
$1.38 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$183.23 M |
$116.78 M |
$36.35 M |
$5.40 M |
| Cost And Expenses |
$183.23 M |
$116.78 M |
$36.35 M |
$5.40 M |
| Interest Income |
$10.22 M |
$268,029.00 |
$361,104.00 |
$344,000.00 |
| Interest Expense |
$6.80 M |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$49,000.00
|
$8,405.00
|
$4,393.00
|
$1,000.00
|
| EBITDA |
-$165.69 M
|
-$3.31 M
|
-$30.73 M
|
-$5.43 M
|
| EBITDA Ratio |
-12.98 |
-0.03 |
0 |
0 |
| Operating Income Ratio
|
-12.99
|
-0.03
|
0
|
0
|
| Total Other
Income/Expenses Net |
$5.49 M
|
-$17.58 M
|
-$5.98 M
|
-$320,000.00
|
| Income Before Tax |
-$160.25 M |
-$21.14 M |
-$36.71 M |
-$5.75 M |
| Income Before Tax Ratio
|
-12.56
|
-0.22
|
0
|
0
|
| Income Tax Expense |
$27,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Net Income |
-$176.94 M |
-$21.14 M |
-$36.71 M |
-$5.75 M |
| Net Income Ratio |
-13.86 |
-0.22 |
0 |
0 |
| EPS |
-2.15 |
-1.11 |
-3.34 |
-1.15 |
| EPS Diluted |
-2.15 |
-1.11 |
-3.34 |
-1.15 |
| Weighted Average Shares
Out |
$82.16 M
|
$18.97 M
|
$17.75 M
|
$17.75 M
|
| Weighted Average Shares
Out Diluted |
$82.16 M
|
$18.97 M
|
$17.75 M
|
$17.75 M
|
| Link |
|
|
|
|
